Dupixent
Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
September 26, 2025Research and Development Dupixent, Regeneron, Sanofi, urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human …
Dupixent improves symptoms in patients with skin of colour, study shows
June 11, 2025Advocacy Development, Medical Education, Research and Development Dermatology, Dupixent, Regeneron, Sanofi, atopic dermatitis, dermatology, underserved populations
Sanofi and Regeneron have announced results from the collaborative phase 4 DISCOVER study, presented at the Revolutionizing Atopic Dermatitis Conference, …
Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment
November 27, 2023Medical Communications COPD, Cardiology, Dupixent, Sanofi, clinical trial
Sanofi and Regeneron have announced results from the second investigational phase 3 NOTUS trial for Dupixent as a treatment for …
Regeneron and Sanofi’s sBLA for Dupixent accepted by FDA for priority review
September 26, 2023Medical Communications Dupixent, Ear Nose & throat, FDA, Regeneron, Sanofi
Regeneron Pharmaceuticals and Sanofi have announced that the US Food and Drug Administration (FDA) has accepted their supplemental Biologics License …
Top Ten most popular articles on Pharmafile.com this week
December 4, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, Dupixent, EMA, UK, Vaccine, top ten
As the year winds to a close, excitement is rising around the efficacy and availability of COVID-19 vaccines around the …
Dupixent becomes first systemic medicine approved in Europe for children with severe atopic dermatitis
November 30, 2020Sales and Marketing Dupixent, EU, Europe, Sanofi
The European Commission has moved to expand the existing authorisation of Sanofi and Regeneron’s Dupixent (dupilumab) in the European Union …
Sanofi’s Dupixent shows strength at Phase 3 in eosinophilic esophagitis
October 27, 2020Manufacturing and Production Dupixent, Sanofi, pharma
Sanofi has lifted the curtain on new Phase 3 data for Dupixent (dupilumab), showing that the drug met all of …
Sanofi’s Dupixent chalks up CHMP recommendation for paediatric severe atopic dermatitis
October 19, 2020Sales and Marketing Dupixent, EMA, Sanofi, atopic dermatitis
Sanofi’s interleukin-4 and -13 inhibitor Dupixent (dupilumab) has been given the recommendation of the European Medicines Agency’s Committee for Medicinal …
Extension study reveals Dupixent’s benefit can last up to three years in moderate-to-severe asthma
September 8, 2020Manufacturing and Production, Research and Development Dupixent, Sanofi, asthma, pharma
New findings have been revealed from an extension study of Sanofi’s interleukin-4 (IL-4) and interleukin-13 (IL-13) inhibitor Dupixent (dupilumab) in …
Sanofi’s Dupixent scores Chinese approval in moderate to severe atopic dermatitis
June 22, 2020Sales and Marketing China, Dupixent, Sanofi, atopic dermatitis, pharma
China’s National Medical Products Administration (NMPA) has moved to approve a 300mg pre-filled pen formulation of Sanofi and Regeneron’s Dupixent …
FDA approves Sanofi’s Dupixent for children with dermatitis
May 27, 2020Research and Development Dupixent, Sanofi, atopic eczema
The FDA has approved Sanofi’s Dupixent (dupilumab) for children between ages 6 to 11 with moderate to severe atopic dermatitis. …
Sanofi and Regeneron’s Dupixent combo impresses in paediatric atopic dermatitis
April 3, 2020Medical Communications, Research and Development Dupixent, Sanofi, atopic dermatitis, pharma
Sanofi and Regeneron have unveiled new Phase 3 data for their IL-4 and IL-13 inhibitor Dupixent (dupilumab), showing strong results …
NICE shoots down Dupixent for severe asthma
March 9, 2020Sales and Marketing Dupixent, NHS, NICE, Regeneron, Sanofi, UK, asthma
NICE, the NHS’ drug watchdog in England and Wales, has announced its decision not to recommend Sanofi and Regeneron’s IL-4 …
European Commission approves Sanofi’s Dupixent in chronic rhinosinusitis with nasal polyposis
October 30, 2019Research and Development, Sales and Marketing Dupixent, EU, Sanofi, pharma
Sanofi’s Dupixent (dupilumab) has secured European approval for the treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP), it has emerged. …
Sanofi’s Dupixent improves skin clearance in paediatric atopic dermatitis
August 7, 2019Research and Development Dupixent, Sanofi, atopic dermatitis, pharma
As the therapy secured approval in Europe for treatment of adolescent patients with moderate-to-severe atopic dermatitis, Sanofi has revealed new …
Latest content
FibroFind appoints Lee Borthwick as CEO
